Table 1.
Demographic data at initiation of recombinant human activated protein C
| Variable | Overall (n = 156) |
|---|---|
| Age, years* | 61 ± 16.8 |
| Male, n (%) | 91 (58) |
| APACHE II* | 29.6 ± 5.8 |
| New organ failure, n (%) | |
| Cardiovascular | 146 (94) |
| Respiratory | 102 (65) |
| Renal | 104 (67) |
| Hematologic | 36 (23) |
| Metabolic | 94 (60) |
| Organ dysfunctions* | 3.1 ± 1.1 |
| ICU type, n (%) | |
| Medical | 72 (46) |
| Surgical/trauma | 84 (54) |
| Baseline precaution or contraindication, n (%)† | 54 (34.6) |
| Infection site, n (%) | |
| Pneumonia | 60 (38) |
| Intra-abdominal | 45 (29) |
| Skin | 25 (16) |
| Urological | 12 (8) |
| Other/unknown | 14 (9) |
| Pathogen, n (%) | |
| Gram positive | 40 (26) |
| Gram negative | 42 (27) |
| Fungal | 6 (4) |
| Mixed | 8 (5) |
| Other/unknown | 60 (38) |
| Corticosteroids, n (%) | 89 (57) |
| Vasoactive agent infusion††,* | 2.1 ± 1 |
| CRRT, n (%) | 40 (26) |
| Mechanical ventilation, n (%) | 143 (92) |
| Platelets, ×103/mm3* | 180 ± 112 |
| INR* | 2.0 ± 1.0 |
| VTE prophylaxis, n (%) | 28 (18) |
Notes:
Data presented as mean ± standard deviation;
according to package labeling and institutional guidelines;
vasoactive agents include: Norepinephrine, phenylephrine, epinephrine, vasopressin, dopamine, and dobutamine. Corticosteroid use was defined as administration of at least 100 mg of hydrocortisone equivalents in the first 24 hours of ICU admission. VTE prophylaxis included use of unfractionated heparin or low molecular weight heparin at doses recommended for prophylaxis according to the American College of Chest Physicians Eighth Conference Evidence Based Guidelines.
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit; CRRT, continuous renal replacement therapy; INR, International Normalized Ratio; VTE, venous thromboembolism.